Screen Time and Myopia — Why It's Not What You Think It Is

Violet Light Therapy for Myopia — What the Early Evidence Actually Shows

The Violet Light Discovery

In 2017, Chakraborty et al. (Proc Natl Acad Sci USA) made an unexpected finding: chicks raised in light that excluded violet wavelengths (360–400nm) developed myopia significantly faster than chicks raised in full-spectrum light. Restoring violet light reversed the myopia progression.

This initiated a new line of research into whether violet light, specifically, is the protective component of outdoor sunlight.

The Mechanism: Dopamine and Cone Opsin

The mechanism appears to involve a novel photopigment—not the traditional cone opsins (sensitive to 420–560nm) but a distinct pathway responsive to deep violet (360–400nm).

Torii et al. (2017) (Proc Natl Acad Sci USA) demonstrated:

• Violet light stimulates dopamine release in the retina and superior colliculus
• Dopamine suppresses form-deprivation-induced myopia in chicks
• This pathway is distinct from the standard visual pathway

Clinical Evidence: LED Spectacle Lenses

Wang et al. (2021) — Violet light-emitting LED spectacles (Ophthalmic Physiol Opt):

• 160 children (8–14 years) with myopia -0.75 to -3.50 diopters
• Randomized to control glasses (standard CR-39) vs. violet LED glasses (wearing 3 hours daily)
• Follow-up: 6 months
• Results:

Safety: No adverse events reported. Violet light at 0.31 mW/cm² (intensity matched to natural daylight) showed no retinal or lens toxicity at 6-month follow-up.

Limitations:

• Single trial; small sample size
• Short follow-up (6 months); long-term safety unknown
• Mechanism not fully established
• Cost and accessibility unknown for commercial devices

Comparison to Red Light Therapy

Red light (650nm) has a similar origin story—promising laboratory evidence followed by limited clinical RCTs.

Huang et al. (2020) — Red light therapy for myopia (Lancet):

• 344 children randomized to control vs. red light therapy (3 minutes, 2× daily, 5 days/week)
• Results: 36% reduction in progression over 1 year
• But: Safety concern reported in 2023—one case of foveal damage in a 12-year-old after 5 months of treatment (Lao et al. 2023, Eye)

Lens Material Matters: Why Most Glasses Block Violet Light

Modern eyeglass lenses block violet light unintentionally:

Lens material comparison (% violet transmission):

• CR-39 plastic (no UV coating): 85–90% transmission
• CR-39 (with UV400): 5–15% transmission
• Polycarbonate: 5–10% (inherently blocks violet)
• High-index plastic: 0–5% (inherently blocks violet)
• Trivex: 5–10%

Lingham et al. (2020) (Ophthalmic Surg Lasers Imaging Retina) suggested that UV400 coatings, while protecting against UVA damage, may paradoxically increase myopia risk by removing violet light—a harmful unintended consequence.

Current Clinical Status

Violet light therapy is not yet a standard treatment. It should be considered:

• Experimental/emerging
• Promising but requiring larger, longer-term RCTs
• Safer than red light (no toxicity reports) but less evidence base
• Not a replacement for outdoor time (which includes violet but much more)

How to Incorporate Violet Light Into a Management Plan

For patients interested in violet light now (acknowledging evidence limitations):

For clinicians: Mention violet light as emerging research; recommend discussing it with patients who are interested in experimental options. Document the conversation.

Outstanding Questions

• Long-term safety beyond 6 months?
• Efficacy in fast-progressing myopia?
• Does violet light add benefit to outdoor time, or is it redundant?
• Optimal intensity and duration?
• Does lens material violet blocking contribute clinically to progression?

The Bottom Line

Violet light is a promising emerging therapy with a single encouraging RCT and compelling mechanism, but it's not ready for standard clinical recommendation. Outdoor time (which includes violet light plus many other factors) remains the evidence-based intervention.

---